Preoperative aspartate transaminase/alanine transaminase ratio as a prognostic biomarker in primary non-muscle-invasive bladder cancer: a propensity score-matched study

Table 3 Univariate and multivariate cox proportional regression analysis for PFS in propensity score-matched cohorts

Variables	Univariate analysis		Multivariate analysis
Variables	HR (95%CI)	P value	HR (95%CI)	P value
Age, n (%)
≤ 60 year	Ref
> 60 year	0.859 (0.505–1.462)	0.576
Gender, n (%)
Female	Ref
Male	0.748 (0.379–1.477)	0.403
Smoking, n (%)	1.128 (0.680–1.872)	0.641
Tumor size
≤ 3 cm	Ref
> 3 cm	1.666 (0.911–3.044)	0.097
Tumor number, n (%)
Solitary	Ref		Ref
Multiple	0.982 (0.591–1.632)	0.943	1.877 (0.997–3.532)	0.051
Re-TURBT, n (%)	0.372 (0.183–0.758)	0.006*	0.301 (0.147–0.617)	0.001*
Pathological stage, n (%)
pTa	Ref		Ref
pT1	1.687 (1.007–2.828)	0.047*	1.534 (0.873–2.694)	0.137
Pathological grade, n (%)
LG or less	Ref		Ref
HG	1.820 (1.085–3.053)	0.023*	1.893 (1.076–3.329)	0.027*
Concomitant carcinoma in situ, n (%)	1.752 (0.859–3.575)	0.123
Type of intravesical therapy, n (%)
Early single instillation	Ref
Adjuvant chemotherapy or BCG	1.061 (0.385–2.920)	0.909
Combined therapy	1.191 (0.507–2.798)	0.688
AST/ALT ratio
Low	Ref		Ref
High	4.165 (2.283–7.599)	< 0.001*	4.771 (2.607–8.734)	< 0.001*

PFS, Progression-free survival; HR, hazard ratio; CI, confidence interval; Ref, Reference; Re-TURBT, restaging transurethral resection of the bladder tumor; LG or less, low grade or papillary urothelial neoplasms of low malignant potential; HG, high grade; BCG, bacillus Calmette-Guerin
*Indicates P < 0.05

ISSN: 1471-2490